GSK Reports P-III (DREAMM-8) Study Results of Blenrep for Treating Relapsed/Refractory Multiple Myeloma (RRMM)
Shots:
- GSK has revealed headline interim analysis results from the P-III (DREAMM-8) study assessing Blenrep + pomalidomide & dexamethasone (PomDex) vs bortezomib + PomDex (SoC) for the 2L & later treatment of patients (n= 302) with RRMM
- The pre-specified interim analysis showed achievement of PFS (1EP), extending the time to disease progression/death & a favorable OS trend with the combination vs SoC. The study is ongoing for OS follow-up. Detailed results will be highlighted at the future conferences
- Blenrep is an ADC formulated with the combination of a humanised B-cell maturation antigen mAb and a cytotoxic agent auristatin F linked through a non-cleavable linker
Ref: GSK | Image: GSK
Related News:- GSK Reports the P-III Results for Blenrep (belantamab mafodotin) in Combiantion with BorDex (dexamethasone) to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
